Literature DB >> 16627991

Regulation of p14ARF through subnuclear compartmentalization.

Ruth A Gjerset1, Keya Bandyopadhyay.   

Abstract

The p53-mediated pathway cell cycle arrest and apoptosis is central to cancer and an important point of focus for therapeutics development. The p14ARF ("ARF") tumor suppressor induces the p53 pathway in response to oncogene activation or DNA damage. However, ARF is predominantly nucleolar in localization and engages in several interactions with nucleolar proteins, whereas p53 is nucleoplasmic. This raises the question as to how ARF initiates its involvement in the p53 pathway. We have found that UV irradiation of cells disrupts the interaction of ARF with two of its nucleolar binding partners, B23 (NPM, nucleophosmin, NO38, numatrin) and topoisomerase I, and promotes an immediate and transient subnuclear redistribution of ARF to the nucleoplasm, where it can engage the p53 pathway (Lee et al, Cancer Res 65:9834-42; 2005). The results support a model in which the nucleolus serves as a p53 upstream sensor of cellular stress, and add to a growing body of evidence that nucleolar sequestration of ARF prevents activation of p53. The results also have therapeutic implications for therapies based on exploiting p53 and other cellular stress response pathways to suppress cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627991     DOI: 10.4161/cc.5.7.2623

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  13 in total

Review 1.  Identification of protein interactions involved in cellular signaling.

Authors:  Jukka Westermarck; Johanna Ivaska; Garry L Corthals
Journal:  Mol Cell Proteomics       Date:  2013-03-12       Impact factor: 5.911

Review 2.  DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer.

Authors:  Ruth A Gjerset
Journal:  J Mol Histol       Date:  2006-07-20       Impact factor: 2.611

3.  p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck.

Authors:  Yang Zhang; Erich M Sturgis; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

Review 4.  The nucleolus under stress.

Authors:  Séverine Boulon; Belinda J Westman; Saskia Hutten; François-Michel Boisvert; Angus I Lamond
Journal:  Mol Cell       Date:  2010-10-22       Impact factor: 17.970

5.  Identification and functional analysis of NOL7 nuclear and nucleolar localization signals.

Authors:  Guolin Zhou; Colleen L Doçi; Mark W Lingen
Journal:  BMC Cell Biol       Date:  2010-09-27       Impact factor: 4.241

Review 6.  Emerging roles of the nucleolus in regulating the DNA damage response: the noncanonical DNA repair enzyme APE1/Ref-1 as a paradigmatical example.

Authors:  Giulia Antoniali; Lisa Lirussi; Mattia Poletto; Gianluca Tell
Journal:  Antioxid Redox Signal       Date:  2013-09-21       Impact factor: 8.401

7.  Potentially functional variants of p14ARF are associated with HPV-positive oropharyngeal cancer patients and survival after definitive chemoradiotherapy.

Authors:  Xicheng Song; Erich M Sturgis; Zhigang Huang; Xiaodong Li; Chao Li; Qingyi Wei; Guojun Li
Journal:  Carcinogenesis       Date:  2013-10-08       Impact factor: 4.944

8.  GLTSCR2 is an upstream negative regulator of nucleophosmin in cervical cancer.

Authors:  Jee-Youn Kim; Young-Eun Cho; Yong-Min An; Sang-Hoon Kim; Yong-Gwan Lee; Jae-Hoon Park; Sun Lee
Journal:  J Cell Mol Med       Date:  2015-03-27       Impact factor: 5.310

9.  A redox mechanism underlying nucleolar stress sensing by nucleophosmin.

Authors:  Kai Yang; Ming Wang; Yuzheng Zhao; Xuxu Sun; Yi Yang; Xie Li; Aiwu Zhou; Huilin Chu; Hu Zhou; Jianrong Xu; Mian Wu; Jie Yang; Jing Yi
Journal:  Nat Commun       Date:  2016-11-25       Impact factor: 14.919

10.  Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation.

Authors:  Magdalena Olbryt; Aleksandra Rusin; Izabela Fokt; Anna Habryka; Patrycja Tudrej; Sebastian Student; Aleksander Sochanik; Rafał Zieliński; Waldemar Priebe
Journal:  Invest New Drugs       Date:  2017-04-17       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.